BRIEF-AstraZeneca says fostamatinib did not meet study goal
2:29am EST
* AstraZeneca shares fall 3 percent, Rigel dives 31 percent (Adds latest share price falls, further analyst reaction)
By Ben Hirschler
LONDON, Dec 13 (Reuters) - An experimental rheumatoid arthritis drug from AstraZeneca proved inferior to Abbott Laboratories' Humira in a clinical study, knocking hopes for one of the few late-stage products in the company's pipeline.
The mid-sized study of fostamatinib - given as a pill rather than injected, as is the case with Humira - showed it was not as good as Abbott's market-leading drug in controlling arthritis symptoms, AstraZeneca said on Thursday.
The news is a blow for Britain's second-biggest drugmaker, the shares of which fell 3 percent by 1520 GMT, and a bigger setback for its small partner, Rigel Pharmaceuticals. The U.S. company's shares tumbled 31 percent on Nasdaq.
AstraZeneca is chasing rival Pfizer in the race to develop a convenient oral alternative to anti-TNF injections like the $9 billion-a-year seller Humira, which have led the field for the past decade.
But while Pfizer's new pill Xeljanz won approval from U.S. regulators last month and proved as good or better than Humira in tests, analysts have been sceptical about prospects for fostamatinib after mixed results in earlier studies, including raised blood pressure in some patients.
The Phase IIb monotherapy results will do nothing to inspire confidence that fostamatinib can become the kind of multibillion-dollar seller that AstraZeneca needs to offset expiring patents on its existing best-selling medicines.
Although it proved better than placebo at some doses, the failure to match Humira's efficacy is "likely to limit the product's commercial potential", Panmure Gordon analyst Savvas Neophytou said.
Salveen Richter, of Canaccord Genuity, said the inferiority to Humira was a "significant negative".
PATENT CLIFF
With this year's loss of exclusivity on schizophrenia drug Seroquel, and Nexium for stomach acid and cholesterol fighter Crestor set for U.S. patent expiries in 2014 and 2016, AstraZeneca faces one of the industry's steepest patent "cliffs".
The six-month Phase IIb clinical trial, which involved 280 patients, is not yet the definitive test for fostamatinib, however.
A more comprehensive assessment of the drug used in combination with other medicines is being carried out in pivotal Phase III studies that will report results in the first half of 2013 and would form the basis of any regulatory submissions.
Even if approved, however, many analysts believe that fostamatinib, which AstraZeneca licensed from Rigel in 2010, could be sidelined as a marginal product in a highly competitive market.
The setback is the latest in a series of pipeline disappointments for AstraZeneca, which recently appointed a new chief executive - former Roche executive Pascal Soriot - to revive its fortunes.
Rheumatoid arthritis has been one of the most lucrative segments for drugmakers, leading to significant investment in the hunt for new products. The autoimmune disease leads to the body's immune system mistakenly attacking healthy tissue, causing inflammation and pain in the joints. (Editing by Erica Billingham and David Goodman) Reuters
Recent RIGL News
- Rigel Announces Reverse Stock Split • PR Newswire (US) • 06/25/2024 12:00:00 PM
- Rigel Pharmaceuticals Completes Transfer of GAVRETO® (pralsetinib) New Drug Application • PR Newswire (US) • 06/24/2024 08:05:00 PM
- Rigel Announces Five Presentations at the EHA2024 Hybrid Congress • PR Newswire (US) • 06/14/2024 07:05:00 AM
- Rigel Highlights New Data in Three Poster Presentations at the 2024 ASCO Annual Meeting • PR Newswire (US) • 06/03/2024 12:13:00 PM
- Rigel to Present at the Jefferies Global Healthcare Conference • PR Newswire (US) • 05/30/2024 12:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/29/2024 11:21:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/29/2024 11:21:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/29/2024 11:20:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/29/2024 11:20:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/29/2024 11:20:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/29/2024 11:19:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 08:06:32 PM
- Rigel Announces Presentations at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress • PR Newswire (US) • 05/23/2024 09:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 08:16:15 PM
- Rigel Reports First Quarter 2024 Financial Results and Provides Business Update • PR Newswire (US) • 05/07/2024 08:01:00 PM
- Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business Update • PR Newswire (US) • 04/30/2024 12:05:00 PM
- Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 04/10/2024 08:30:00 PM
- Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma • PR Newswire (US) • 04/04/2024 12:05:00 PM
- Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer • PR Newswire (US) • 03/12/2024 12:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 09:10:40 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/05/2024 09:06:00 PM
- Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • PR Newswire (US) • 03/05/2024 09:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/02/2024 12:16:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/02/2024 12:15:44 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/02/2024 12:15:20 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM